DDX5 and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC), DDX5 overexpression sustains Wnt/β-catenin signaling, promotes nuclear accumulation of β-catenin, and co-activates cyclin D1 and c-Myc expression (Li et al., 2021; Wang et al., 2015), while in thyroid cancer it enhances metastatic potential through interaction with E2F1 (Yuan et al., 2020).